上海莱士：血液制品中的罕见病药物仍适用3%简易征收

Group 1 - The core viewpoint of the article is that Shanghai Laishi (002252) has responded to investor inquiries regarding the impact of the new national VAT policy on blood products, specifically that rare disease medications will still be subject to a simplified 3% tax rate, while other blood product businesses will no longer benefit from this rate [1] - The adjustment in tax policy is described as an industry-wide unified policy, indicating that it will affect the entire sector [1] - The company plans to mitigate the impact of this policy change by optimizing procurement management and enhancing input tax deduction management in compliance with regulations [1]